On May 17, Hims & Hers Health raised its 2026 revenue guidance to $3 billion, exceeding market expectations. The company maintains a long-term target of at least 20% EBITDA margins by 2030. However, it faces short-term margin pressures from branded GLP-1 drugs and international scaling.
